Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study
OPEN Vaccine | 4 Sep 2017
L Szenborn, IV Osipova, H Czajka, SM Kharit, T Jackowska, N François, MA Habib and D Borys
Abstract
Immunization with pneumococcal vaccines is an important prophylactic strategy for children with asplenia or splenic dysfunction, who are at high risk of bacterial infections (including S. pneumoniae). This study aimed to assess immunogenicity and safety of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, GSK) in this at-risk population.
- Tweets*
- 0
- Facebook likes*
- 0
- Reddit*
- 0
- News coverage*
- 0
- Blogs*
- 0
- SC clicks
- 1
- Concepts
- Polysaccharide encapsulated bacteria, Microbiology, Otitis media, Pneumococcal conjugate vaccine, Haemophilus influenzae, Streptococcus pneumoniae, Immune system, Pneumonia
- MeSH headings
- -
comments powered by Disqus
* Data courtesy of Altmetric.com